Search Orphan Drug Designations and Approvals
-
| Generic Name: | Bexarotene | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Targretin | ||||||||||||||||
| Date Designated: | 06/18/1999 | ||||||||||||||||
| Orphan Designation: | Treatment of cutaneous T-cell lymphoma. | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Eisai, Inc. 300 Tice Blvd Woodcliff Lake, New Jersey 07677 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Bexarotene |
|---|---|---|
| Trade Name: | Targretin | |
| Marketing Approval Date: | 12/29/1999 | |
| Approved Labeled Indication: | Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. | |
| Exclusivity End Date: | 12/29/2006 | |
| Exclusivity Protected Indication* : | ||
-
